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Abstract
Background: The prevalence of diabetes mellitus (DM) has increased exponentially in recent
years, with 100 million people expected to develop diabetes in the coming 15 years. The impact
of medical therapy on the incidence of new onset DM is not clear. We performed a systematic
review and meta-analysis to study the impact of angiotensin-converting enzyme inhibitors
(ACEIs) and angiotensin receptor blockers (ARBs) on the incidence of new onset DM.
Methods: MEDLINE, EMBASE, BIOSIS, Cochrane databases from inception until Febru-
ary 2009 for randomized controlled trials (RCT) that reported new incident DM with ACEI or
ARB therapy. A total of 18 RCT are included in this meta-analysis. A random-effect model
was used and between-studies heterogeneity was estimated with I2.
Results: There were 50,451 patients randomized to ACEI or ARB and 50,397 patients randomized
to other therapies. ACEI/ARB use was associated with a decrease in new onset DM (RR 0.78,
95% CI 0.70–0.88, p = 0.003 for ACEI and RR 0.8, 95% CI 0.75–0.86, p < 0.0001 for ARB).
Treating 100 patients with ACEI or 50 patients with ARB prevents one case of new onset DM.
Conclusions: The cumulative evidence suggests that the use of ACEI/ARB prevents diabetes
mellitus. This finding may be of special clinical benefit in patients with hypertension and pre-
diabetes or metabolic syndrome. (Cardiol J 2010; 17, 5: 448–456)
Key words: angiotensin converting enzyme inhibitors, angiotensin receptor
blockers, diabetes mellitus
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Introduction
The prevalence of diabetes in the United States
in 2007 was 23.6 million people, or 7.8% of the pop-
ulation (17.9 million with diagnosed, and 5.7 million
people with undiagnosed, diabetes) [1]. Diabetes
was the seventhcommonest cause of death listed
on U.S. death certificates in 2006 [2]. Overall, the
risk of death among people with diabetes is nearly
twice that of people without diabetes of a similar
age [1]. Even patients with pre-diabetes (impaired
glucose tolerance and/or impaired fasting glucose)
have an increased risk of heart disease and stroke [3].
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The Diabetes Prevention Program showed that life-
style intervention in patients with pre-diabetes re-
duced the development of diabetes by 58% over
a three-year period [4, 5].
Previous studies have shown a relationship
between increased insulin resistance and renin an-
giotensin aldosterone system (RAAS) [6, 7]. Meta-
bolic abnormalities linked to diabetes mellitus (DM)
lead to activation of RAAS, and thereby increased
angiotensin II and aldosterone levels [8]. Blocking
angiotensin II decreases proinflammatory media-
tors and the oxidative stress. This in turn can pre-
vent and delay the onset of DM, as well as prevents
cardiac and renal events [9].
Multiple randomized controlled clinical trials
have reported subgroup analysis in regards to the
incidence of DM in patients receiving angiotensin
converting enzyme inhibitors/angiotensin receptor
blockers (ACEIs/ARBs) in comparison to a place-
bo. However, most of these studies have been un-
derpowered in terms of confirming the beneficial
effects of ACEIs/ARBs in preventing new onset DM
[10, 11]. We therefore conducted a systematic re-
view and meta-analysis of all randomized controlled
trials (RCT) using ACEIs or ARBs and reporting
the incidence of new onset diabetes at the end of
the study.
Methods
Search strategy
We conducted a search in MEDLINE (1948 to
July Week 2, 2009), EMBASE (1988 to 2009 Week
29), COCHRANE databases (from inception until
the second quarter of 2009) and BIOSIS for randomi-
zed controlled trials that involved the use of ACEIs
or ARBs and onset of new onset DM. Various terms
were used for search including new diabetes, pre-
vent diabetes, diabetes mellitus, ACEIs or ARBs,
angiotensin converting enzyme inhibitors, angio-
tensin receptor blockers, and others. The search
was performed without any language restrictions.
The search was limited to human subjects. When
an abstract from a meeting and a full article referred
to the same trial, only the full article was included
in the analysis. When there were multiple reports
from the same trial, we used the most complete and/
/or most recently reported data.
Inclusion and exclusion criteria
All trials searched were assessed for: 1) randomi-
zation, 2) study duration of at least one year, 3) re-
ported incidence of new onset diabetes as a pre-spec-
ified point or as a part of post-hoc analysis. Rando-
mized controlled trial was defined according to the
National Library of Medicine criteria (http://
//www.nlm.nih.gov/mesh/pubtypes2001.html). Dia-
betes was defined using the American Diabetes As-
sociation (ADA) criteria in most of the trials (fasting
blood glucose levels ≥ 126 mg/dL on two different
occasions) [12]. Data for each trial was abstracted by
an investigator (MA) and was confirmed by a sec-
ondary investigator (AO). Trials which did not meet
the above requirements were excluded from the
meta-analysis.
Statistical analysis
The meta-analysis was performed by comput-
ing relative risks (RR) using a random-effects mod-
el. Quantitative analyses were performed on an in-
tention-to-treat basis. RR for new onset diabetes
was calculated along with the 95% confidence in-
tervals (CIs). The number needed to treat to pre-
vent one event was calculated by the inverse of the
pooled absolute risk reduction. Between studies
heterogeneity was analyzed by means of I2 =
= [(Qdf)/Q] × 100%, where Q is the c2 statistic and
df is its degrees of freedom. This describes the
percentage of the variability in effect estimates that
is due to heterogeneity rather than sampling
error (chance). Publication bias was assessed graph-
ically using a funnel plot. All analyses were performed
with RevMan Analyses Version 5.0.20 (© Nordic Co-
chrane Centre, Ringshopitalet 2008).
Results
Overall, we found 408 articles on the primary
search, of which 173 were excluded as they were
not randomized controlled trials (Fig. 1). From the
Figure 1. Summary of search strategy results; RCT —
randomized controlled trials.
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remaining 235 articles, we included 18 trials in to-
tal (Fig. 1), with ten using ACEIs (Table 1) and eight
using ARBs (Table 2).
Trials involving ACEIs i.e. Studies of Left Ven-
tricular Dysfunction (SOLVD) [13], The second
Swedish Trial in Old Patients with hypertension
(STOP-2) [14], African American Study of Kidney
disease and hypertension (AASK) [15], The Heart
Outcomes Prevention Evaluation Study (HOPE)
[16], Ischemia Management with Accupril post-by-
pass graft via Inhibition of the converting Enzyme
(IMAGINE) [17], Diabetes REduction Approaches
with ramipril and rosiglitazone (DREAM) [18], An-
tihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) [19], Cap-
topril Prevention Project (CAPP) [20], Prevention
of Events with Angiotensin Converting Enzyme
Inhibition Trial (PEACE) [21] and The second Aus-
tralian National Blood Pressure study (ANBP2) [22]
had a total number of 49,318 patients. Only DREAM
[18] trial in ACEIs group had incidence of new on-
set DM as the pre-specified end point, others were
post-hoc analysis. ALLHAT [19] had the largest
number of patients while AASK [15] had the small-
est number of patients in this sub-group. Four tri-
als i.e. STOP2 [14], DREAM [18], CAPP [20] and
IMAGINE [17] failed to reach statistical signifi-
cance. However, results did show a trend favoring
use of ACEIs for prevention of DM. The total num-
ber of patients developing DM in this sub-group was
3,675 (1,665 in ACEIs group and 2,010 in placebo/
/other group). RR ratio was 0.78, 95% CI 0.70–0.88
and p < 0.0001 (Fig. 2).
Trials involving ARBs i.e. Anti-hypertensive
Treatment and Lipid Profile in a North of Sweden
Efficacy Evaluation (ALPINE) [23], Candesartan in
Heart Failure — Assessment of Reduction in Mor-
tality and Morbidity (CHARM) [24], Losartan Inter-
vention For Endpoint Reduction in hypertension
study (LIFE) [25], Telmisartan Randomised As-
sessmeNt Study in ACE iNtolerant subjects with
cardiovascular Disease (TRANSCEND) [26], Can-
desartan Antihypertensive Survival Evaluation in
Japan (CASE-J) [27], Prevention Regimen for Ef-
fectively Avoiding Second Strokes (PRoFESS) [28],
The Study on Cognition and Prognosis in the Eld-
erly (SCOPE) [29] and Valsartan Antihypertensive
Long-term Use Evaluation (VALUE) [30] had a to-
tal number of 51,530 patients. Four trials in the
ARBs group i.e. ALPINE [23], CASE [27], VALUE
[30] and PRoFESS [28] had incidence of new onset
DM as a pre-specified end point, while the rest were
again post-hoc analysis. PRoFESS [28] had the larg-
est number of patients, while ALPINE [23] had the Ta
b
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smallest number of patients in this sub-group.
Three trials i.e. SCOPE [29], PRoFESS [28] and
TRANSCEND [26] failed to reach statistical signi-
ficance. However, results did show a trend favoring
use of ARB for prevention of DM. The total num-
ber of patients developing DM in this sub-group was
3,505 (1,561 in the ARB group and 1,944 in the pla-
cebo/other group). RR was 0.80, 95% CI 0.75–0.86
and p < 0.00001 (Fig. 2).
The mean duration of follow-up ranged from one
year to 6.1 years. ACEIs/ARBs in the current meta-
analysis were compared with other anti-hypertensive
agents including beta-blockers, calcium channel block-
ers, and diuretics as well as with a placebo. Cumula-
tive data from both sub-groups show a total of 100,848
patients. Incidence of new onset DM was 7,170 (7.1%)
in total, with 3,216 patients in the ACEIs/ARBs group
(6.37%) against 3,954 patients in the placebo/other
group (7.84%). RR was 0.80, 95% CI 0.75–0.86 (Fig. 2).
Reduction in risk of new onset DM was 22% for the
ACEI group, 20% for the ARBs group and ~20%
for the ACEIs/ARBs group. The absolute risk reduc-
tion associated with ACEIs therapy to prevent new
onset DM was 0.01 (1%) while the absolute risk re-
duction associated with ARBs therapy to prevent
new onset DM was 0.02 (2%). Thus treating 100 pa-
tients with ACEIs or 50 patients with ARBs prevents
one case of new onset diabetes.
On further sub-analysis of the data, the total
number of patients in ACEIs/ARBs trials reporting
the incidence of new onset DM as a pre-specified
end point was 33,096. The total number of patients
with new onset DM was 2,854 (8.6%) with 1,303
(7.87%) in the ACEIs/ARBs group and 1,551 (9.37%)
in the placebo/other group. RR with ACEIs/ARBs
for new onset DM was calculated to be 0.83 with
95% CI 0.74–0.94 (Fig. 3).
On further breakdown of data for trials report-
ing the incidence of new onset DM as a part of post-
hoc analysis, there were 67,752 patients. The total
number of patients with new onset DM was 4,316
(6.3%) with 1,913 (5.6%) in the ACEIs/ARBs group
and 2,403 (7.0%) in the placebo/other group. RR for
ACEIs/ARBs studies with incidence of DM report-
ed as a part of post-hoc analysis: the RR was for new
onset DM with ACEIs/ARBs was calculated to be
0.78 with 95% CI 0.72–0.85 (Fig. 4).
The test for heterogeneity showed some dif-
ference in effect among the studies as evident by I2
estimates for different outcomes (I2 > 50%), while
it was not evident for the ARBs sub-group (I2 < 50%).
Sensitivity analysis was done with respect to ACEIs
vs ARBs use, follow-up duration £ vs ≥ 4 years,
age £ vs ≥ 65 years, tissue specific ACEIs use vsTa
b
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Figure 2. Forest plot of the meta-analysis. Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor
blocker (ARB) use was associated with a decrease in the incidence of diabetes mellitus; M-H — Mantel-Haenszel;
CI — confidence interval.
Figure 3. Forest plot of comparison with diabetes mellitus as a pre-specified end-point (ACEI/ARB); CI — confidence
interval; ACEI — angiotensin converting enzyme inhibitor; M-H — Mantel-Haenszel; ARB — angiotensin receptor
blocker.
453
Mouaz Al-Mallah et al., ACEIs or ARBs and diabetes mellitus
www.cardiologyjournal.org
others, pre-specified endpoint or post-hoc analysis,
and candesartan use vs use of other medications among
ACEIs/ARBs. There was no statistically significant
difference with all the p values more than 0.05 as
shown in Table 3. The funnel plot analysis showed
asymmetrical distribution of RR estimates with
evidence of publication bias as shown in Figure 5.
Discussion
This meta-analysis of 100,848 patients shows
a statistically significant 20% cumulative relative
risk reduction in the incidence of new onset diabe-
tes with the use of ACEIs or ARBs. These results
are consistent with previous analyses of smaller
samples, showing the beneficial effects of ACEIs
and ARBs in preventing new onset diabetes [10, 11].
Insulin mediated glucose uptake in skeletal
muscles is important for the regulation of blood glu-
cose levels. ACEIs, by suppressing angiotensin II
and/or increasing bradykinin (BK), have been
shown to increase insulin sensitivity in skeletal
muscles [31]. ACEIs increase BK levels by inhibi-
tion of kininase II mediated degradation [32]. This
leads to an increased production of prostaglandins
and nitric oxide which improves exercise induced
Table 3. Sensitivity analysis.
Variables Yes No P
RR, M-H, randomization RR, M-H, randomization
(95% CI) (95% CI)
ACEI vs ARB (Yes vs No) 0.78 (0.70–0.88) 0.80 (0.75–0.86) 0.710
Follow up £ 4 years (Yes vs No) 0.76 (0.64–0.91) 0.80 (0.75–0.86) 0.590
Age £ 65 years (Yes vs No) 0.75 (0.62–0.90) 0.80 (0.76–0.85) 0.505
Tissue specific ACEI (Yes vs No) 0.80 (0.70–0.92) 0.79 (0.73–0.86) 0.878
Candesartan use (Yes vs No) 0.77 (0.63–0.93) 0.80 (0.75–0.86) 0.712
Pre-specified endpoint vs post-hoc analysis 0.83 (0.74–0.94) 0.78 (0.72–0.85) 0.431
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker; RR — relative risk; M-H — Mantel-Haenszel; CI — confidence
interval
Figure 4. Forest plot of comparison with diabetes mellitus incidence as post-hoc analysis (ACEI/ARB); CI — confiden-
ce interval; ACEI — angiotensin converting enzyme inhibitor; M-H — Mantel-Haenszel; ARB — angiotensin receptor
blocker.
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glucose metabolism and muscle sensitivity to insu-
lin, thereby increased glucose uptake [33, 34]. It
was reported that ACEIs and physical activity have
additive effects on lowering serum insulin concen-
trations and improving HOMA-R (insulin resis-
tance); this indicates that ACEIs may improve in-
sulin sensitivity in hypertensive patients with in-
sulin resistance.
ARBs, with partial PPARg agonist activity, have
also been shown to improve insulin sensitivity in
non-modulating hypertensive patients. Unlike mo-
dulating hypertensive patients, who normally handle
high salt intake, non-modulating hypertensive pa-
tients are salt sensitive and develop insulin resis-
tance as well as oxidative stress [35, 36].
ACEIs have been shown to be beneficial in the
secondary prevention of microvascular complica-
tions. Low-dose ramipril significantly improved
capillary refill velocity during post-occlusive hype-
remia in hyperglycemic patients without esta-
blished complications [37]; this demonstrates that
ACEIs improve microcirculation in hyperglycemic
patients and are of benefit in preventing microvas-
cular complication in diabetic patients.
When compared, ACEIs and ARBs have been
proven to be equally effective in treating hyperten-
sion in DM. Comparison was made between losar-
tan (ARB) and fosinopril (ACEI) with respect to
blood pressure (BP), creatinine clearance (Ccr) and
urinary albumin excretion (UAE), as well as meta-
bolic parameters. Ccr was similar in both groups.
UAE was lower in both groups at 1 and 6 months,
although the antiproteinuric effect of losartan was
somewhat decreased at 6 months [38]. Thrombo-
modulin (TM) has been shown to be a marker of
endothelial cell damage, along with an increased
urinary albumin excretion in patients with DM.
Figure 5. Funnel plot for publication bias.
Treatment with ACEIs decreased both UAE and
TM [39].
Congestive heart failure (CHF) is found in 10–
–15% of diabetics and is an independent risk factor
for DM and vice versa. Insulin resistance has been
shown to be directly responsible for diastolic dys-
function of the heart [40]. CHF in patients with DM
has a poor prognosis and good glycemic control
improves its prognosis [41]. ACEIs and ARBs pro-
vide an added benefit for CHF patients by prevent-
ing diabetes.
Results of Nateglinide And Valsartan in Im-
paired Glucose Tolerance Outcomes Research
(NAVIGATOR) are expected to be released later
this year [42]. This was a multinational, double blind
and randomized trial that enrolled patients from Jan-
uary 2002 until January 2004. One of the three pri-
mary end points of this trial was to look for reduc-
tion in the incidence of new onset type 2 diabetes
with reduction in post parandial hyperglycemia,
blockade of RAAS, or both. The results of this trial
will be a valuable addition.
This meta-analysis clearly shows a significant
beneficial effect for ACEIs and ARBs in preventing
diabetes. However, only one case would be prevent-
ed by treating 50–100 patients. It is therefore not
justified to use these medications for simple pre-
vention. However, the use of these medications to
treat hypertensive and CHF patients at risk for di-
abetes is highly recommended, since there is the
added benefit of diabetes prevention. Future cost-
effectiveness analysis are needed to determine the
cost-effectiveness of ACEI and ARB in preventing
diabetes in a specific patient population including
patients with pre diabetes or hypertension.
Limitations of the study
The current meta-analysis has some limita-
tions.  Four of the ten trials i.e. STOP2 [12], AASK
[11], ANBP2 [20] and CAPP [14] in the ACEIs group
were open label trials while six others were double
blinded randomized controlled trials. Likewise, two
of eight trials i.e. CASE [21] and PRoFESS [16] in
the ARBs group were open label trials, while the
rest were double blinded randomized controlled
trials. As mentioned above, only the DREAM [13]
trial in the ACEIs group had incidence of new on-
set DM as a pre-specified end point, while the oth-
ers were post-hoc analysis.
Likewise, only four trials in the ARBs group
i.e. ALPINE [17], CASE [21], VALUE [22] and
PRoFESS [16] had incidence of new onset DM as
a pre-specified end point, while the rest were again
post-hoc analysis. Another potential limitation
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would be differences between drugs in the same
group that are ignored in this approach. A signifi-
cant limitation of the study is the use of various anti-
hypertensive drugs, especially thiazide diuretics
and conventional beta-blockers, in the placebo arm
which are well known for inducing impaired glucose
metabolism and could have very likely affected the
results of the study.
Conclusions
In summary, this meta-analysis of more than
100,000 patients clearly points towards a beneficial
effect of ACEI and ARB in preventing new onset
diabetes mellitus. Additional prospective double-
-blinded randomized controlled trials will be need-
ed to confirm the importance of ACEI and ARB in
preventing new onset diabetes.
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